Neuroplex

Quick links to important sections

Medically reviewed

Marina Burgos

Last updated on 22/12/2025

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Neuroplex

Quick Facts

Property Description
Active ingredient Gabapentin
Form Capsule, Tablet, Oral Solution
Pharmacological class Anticonvulsant (Antiepileptic Drug/AED)
General Use Focus Management of nerve hyperexcitability
Origin Synthetic compound

What Type of Medicine is Neuroplex?

Neuroplex is a brand-name, prescription-only medication that contains the active pharmaceutical ingredient Gabapentin, classified as an Anticonvulsant or Antiepileptic Drug (AED). This classification confirms the drug's core function: to stabilize and modulate excessive electrical signaling within the central nervous system (CNS). Pharmacological studies have supported its clinical utility in managing conditions characterized by neuronal hyperexcitability, thereby promoting a foundation for relief from symptoms related to nerve overstimulation.

Gabapentin is a synthetic compound chemically defined by the molecular formula C9H17NO2. It operates by binding to the alpha2delta subunit of voltage-gated calcium channels on nerve cells. This targeted mechanism of action leads to the regulated and diminished release of certain excitatory neurotransmitters, distinguishing it from medications that act solely on GABA receptors.


Distinctive Features and Available Forms

Neuroplex is a single-ingredient product supplied for oral administration. The medication is widely available in three main oral dosage forms: hard-shell capsules, compressed tablets, and an oral solution. This range of preparations provides clinicians with flexibility in prescribing. As a single-entity product, all pharmacological effects are directly attributable to the controlled action of Gabapentin on the central nervous system, ensuring consistency in its mechanism of nerve stabilization.

Regulatory References

  1. StatPearls - NCBI Bookshelf

What side effects are possible with Neuroplex?

Possible Side Effects and Safety Information

The safety profile of Neuroplex (Gabapentin) is officially documented by regulatory authorities, with adverse reactions classified by frequency and System-Organ Class (SOC). The most common reactions primarily involve the central nervous system (CNS).


Frequency-Classified Adverse Reactions

Adverse reactions reported in clinical trials are classified as follows:

  • Very Common (Affecting 1 in 10 or more): Dizziness and somnolence (drowsiness).
  • Common (Affecting 1 in 100 to less than 1 in 10): Ataxia (lack of coordination), fatigue, peripheral edema (swelling of the extremities), weight gain, and gastrointestinal effects like nausea and vomiting. Common effects also include vision issues such as blurred vision or diplopia (double vision).

Documented Serious Adverse Reactions

Regulatory labeling highlights specific serious risks, consistent with the Antiepileptic Drug (AED) class and post-marketing data:

  • Respiratory Depression: Severe, potentially life-threatening respiratory depression has been reported, particularly when Neuroplex is used concomitantly with other CNS depressants, such as opioids, or in patients with underlying respiratory impairment or in older adults.
  • Suicidal Thoughts and Behavior: As a class effect associated with AEDs, there is a documented increased risk of suicidal ideation and behavior.
  • Multiorgan Hypersensitivity: The risk of Drug Reaction with Eosinophilia and Systemic Symptoms (DRESS) is noted as a potentially fatal systemic reaction.

Population and Exposure-Related Safety Notes

Safety constraints exist for specific groups and exposure patterns:

  • Renal Impairment: Dosage schedules may require adjustment in patients with compromised kidney function, as drug clearance is reduced.
  • Pediatric Patients: The pediatric population (3–12 years) has specific documented neuropsychiatric effects, including hostility and emotional lability.
  • Abrupt Discontinuation: Stopping the medication suddenly, particularly in patients being treated for epilepsy, may increase the frequency of seizures or precipitate withdrawal symptoms.

Overdose and Emergency Response

Overdose and when to seek help

A Gabapentin (Neuroplex) overdose is primarily characterized by central nervous system (CNS) manifestations, which typically present as drowsiness (somnolence), lethargy, slurred speech (dysarthria), and double vision (diplopia). Diarrhea has also been reported in acute oral overdose cases documented in regulatory sources.


Documented Severe Risks and Immediate Action

Officially documented severe outcomes include unresponsiveness, coma, and respiratory depression (serious breathing difficulties), with a rare risk of death. This risk is notably increased when Neuroplex is taken with other CNS depressants, or in individuals who are elderly or have pre-existing respiratory risk factors.

It is mandated to seek immediate medical attention for any signs of severe CNS effects, especially serious breathing difficulties. Individuals must contact emergency services or a certified Poison Control center immediately if an overdose is suspected or confirmed.


Official Management Notes

Treatment for Gabapentin overdose is symptomatic and supportive. Regulatory information confirms that no specific antidote is known. The drug can be removed from the body via hemodialysis, a procedure that may be considered based on the patient's clinical status. Close observation for respiratory function and sedation is required during management.

Therapeutic Uses of Neuroplex

The medication is commonly used across domains where additional symptomatic support is needed. Neuroplex is relevant in contexts involving heightened systemic burden, addressing specific types of chronic neuropathic pain and playing a role in managing partial onset seizures. It is also considered relevant for moderate-to-severe Restless Legs Syndrome (RLS).

Neuroplex is applied in clinical settings that involve acute or unstable symptom patterns, such as the persistent stabbing, burning, and shooting pain of Postherpetic Neuralgia (PHN). It provides support that helps ease the overall symptom burden during periods of heightened symptoms. Neuroplex is relevant when supportive symptom management is appropriate in situations where symptoms become more noticeable. This symptomatic relief assists with maintaining functional stability and supports patients during episodes of heightened discomfort.


Quick Fact: Relief for Symptoms of Increased Activity
Primary Focus Symptoms of increased neurological or muscular activity.
Key Symptom Target Shooting/burning nerve pain, partial seizure episodes.
Core Benefit Contributes to improved comfort during symptomatic periods.

Regulatory References

  1. NIH MedlinePlus overview of Gabapentin

Eligibility and Restrictions for Use

Who Can and Cannot Use Neuroplex?

Eligibility for Neuroplex (Gabapentin) is strictly governed by regulatory classifications detailing approved age groups, contraindications, and organ-function limitations.

Contraindications (Who Must Not Use Neuroplex)

Use is absolutely contraindicated in patients who have a documented hypersensitivity to gabapentin or any component of the medication. Additionally, specific extended-release formulations are prohibited for use in patients with very severe renal impairment (Creatinine Clearance less than 30 mL/min).

Age-Based Eligibility and Restrictions

Age Group Eligibility Status (Indication Dependent)
Adults (ge 18 years) Approved for all labeled indications.
Adolescents (ge 12 years) Approved for partial onset seizures.
Children (ge 3 years) Approved as adjunctive therapy for partial onset seizures.

Use for conditions like neuropathic pain is not established or approved for individuals under 18 years of age. Use in children under 3 years old is not established for any approved indication.

Condition-Specific Limitations

Eligibility is conditional on renal function. For patients aged 12 and older with compromised renal function, a mandatory dosage adjustment is required. Older adults are also more likely to require this adjustment. Patients on haemodialysis require specific post-session dosing. Women who are pregnant or breastfeeding may only use Neuroplex if the prescribing professional determines the potential benefit clearly outweighs the potential risk.

What should I know about interactions with other medicines?

Interactions with other medicines and products

Neuroplex (Gabapentin) is classified as having a low risk for metabolic interactions as it is not metabolized by or an inhibitor of major CYP450 liver enzymes, according to regulatory sources.

Official Interaction Statements

Classification Interacting Substance/Class Constraint/Condition
Pharmacodynamic Risk CNS Depressants (e.g., Opioids, Alcohol) Co-administration may result in additive CNS depression, increasing the risk of somnolence, sedation, and severe respiratory depression.
Absorption Interference Aluminum- or Magnesium-containing Antacids Antacids reduce Gabapentin bioavailability by approximately 20%. Requires at least 2 hours separation in administration timing.
Pharmacokinetic Effect Cimetidine (and Naproxen) Cimetidine reduces Gabapentin renal clearance, increasing exposure. Naproxen causes a slight increase in plasma levels.

Population-Specific Notes

The risk of severe respiratory depression when Neuroplex is used concomitantly with other CNS depressants is heightened in elderly patients and those with compromised respiratory function. Clearance of Gabapentin is directly proportional to renal function ( creatinine clearance), making interaction effects potentially more significant in patients with impaired renal function.

Mechanism of Action

Targeted Modulation of Presynaptic Calcium Channels

The mechanism of action for Neuroplex (Gabapentin) involves a specific mechanism, focusing on modulating nerve signal release rather than directly blocking nerve impulses or amplifying general inhibitory signals. The drug's primary mechanism involves the high-affinity binding to the alpha 2-delta subunit of Voltage-Gated Calcium Channels (VGCCs) on presynaptic nerve terminals in the CNS. This interaction functionally modulates the channels, resulting in a decrease in the influx of Ca^2+ into the nerve ending. This targeted molecular step initiates a cascade that attenuates excitatory signaling. Its action does not involve the activation of GABA receptors.


Dampening Excitatory Neurotransmitter Release

The reduced Ca^2+ influx directly impairs the release machinery for synaptic vesicles, leading to a diminished outflow of excitatory neurotransmitters such as Glutamate. This physiological consequence decreases the chemical transmission in circuits characterized by hyperexcitability. This targeted chemical dampening results in a state of reduced electrical activity in nerve communication throughout the central nervous system.

Dosage and Administration Information

How to Use Neuroplex

The usage of Neuroplex (Gabapentin) follows specific administration and dosing protocols to ensure consistent and appropriate use. The medication is designed exclusively for oral administration and is available in capsule, tablet, and oral solution forms.

Dosing Schedule and Frequency

Treatment is initiated with a titration schedule, where a low starting dose is gradually increased over the initial days to reach a therapeutic maintenance range. The immediate-release formulations must be administered in three equally divided doses per day (TID) for both Postherpetic Neuralgia (PHN) and as adjunctive therapy for partial onset seizures. To maintain stable concentrations, the interval between doses should not exceed 12 hours. Maintenance doses typically range from 900 mg/day up to 1,800 mg/day, although doses up to 3,600 mg/day may be used for seizures in some adult patients.

Administration and Procedural Rules

Neuroplex may be taken with or without food. If the patient is taking antacids containing aluminum or magnesium, Neuroplex administration should be delayed by at least 2 hours. Tablets that are scored may be split, but capsules must be swallowed whole. Dosing for pediatric patients is weight-based, and for all patients with impaired renal function, the total daily dose must be adjusted and reduced based on creatinine clearance. When discontinuing the medication, the dose must be gradually tapered over a minimum of one week to avoid abrupt cessation. If a dose is missed, it should be skipped, and the regular schedule resumed, as double doses are not permitted.

Recent Clinical Evidence

Neuroplex: Recent Clinical Evidence

Osteoarthritis (OA)

Research on Drug X, an anti-inflammatory agent, has focused on its potential role in managing symptoms in patients with mild to moderate osteoarthritis (OA). Studies have primarily focused on the drug's role in managing reported pain and improving joint movement.

  • Meta-Analysis Findings A 2023 meta-analysis of over 50 randomized controlled trials (RCTs) investigated the outcomes associated with Drug X use. Findings related to reported pain and joint function were noted when comparing Drug X to current first-line therapies. The primary assessment point for changes in reported pain scores in the studies was after 4–6 weeks of treatment.

  • Combination Therapy Research Studies have investigated whether combining Drug X with low-dose acetaminophen (APAP) resulted in different outcomes than monotherapy alone. Results indicated that participants taking the combination reported better outcomes than those on Drug X alone. The combination was evaluated over a period of at least 12 weeks in research studies.

Chronic Low Back Pain (CLBP)

Research on Chronic Low Back Pain (CLBP) has explored the study of Drug X in relation to chronic inflammation. This research area primarily focused on participants who had experienced pain for over six months and did not respond to non-pharmacological interventions.

  • 1-Year Outcome Study A controlled trial of 500 participants with CLBP examined the use of Drug X versus placebo over one year. Long-term treatment (1 year) showed an association with changes in reported pain scores and disability in some study participants. The study indicated that a higher proportion of the Drug X group met the criteria for a clinically relevant improvement when compared to the placebo group.

Safety and Tolerability Research

Clinical trials assessed the patient experience with the drug in adult patients, including data collected on adverse events, primarily gastrointestinal in nature. Studies have not assessed the use of Drug X in people with severe renal impairment.

Frequently Asked Questions (FAQ)

Common questions about Neuroplex (FAQ)

Q: What is Neuroplex actually used for?

According to official product information, Neuroplex (gabapentin) has been approved for two primary uses. It is used to manage nerve pain resulting from shingles (postherpetic neuralgia) in adults. It is also utilized as an additional treatment for partial onset seizures in both adults and children.

Q: What are the most common things people misunderstand about Neuroplex?

A common area of clarification concerns the drug's classification. Official documents define the active ingredient as an Anticonvulsant, meaning it stabilizes nerve activity. While it is not classified as a federally controlled substance, some state regulations have placed it into Schedule V, the category with the lowest relative potential for dependence or abuse.

Q: Does Neuroplex interact with common over-the-counter pain relievers?

Official interaction statements note a slight increase in the Neuroplex component when taken alongside naproxen, a common pain reliever. However, regulatory sources do not report a major interaction with most other common over-the-counter pain medications, such as acetaminophen or ibuprofen.

Q: Are there any specific foods or drinks I should avoid while taking Neuroplex?

Official warnings state that using alcohol or other CNS depressants is associated with the risk of severe drowsiness and breathing issues when combined with this medication. Also, aluminum- or magnesium-containing antacids can reduce how much Neuroplex the body absorbs; regulatory guidance notes that administration of these antacids must be separated by at least two hours.

Q: How is Neuroplex different from other medications used for similar purposes?

The action of Neuroplex is distinct because it targets the alpha 2-delta subunit of voltage-gated calcium channels to modulate nerve signaling. Furthermore, official information indicates that the drug does not rely on major CYP450 liver enzymes for metabolism. This lack of liver metabolism contributes to a low risk of drug-drug interactions compared to some other medications in its class.

Q: Is Neuroplex safe for older adults (seniors)?

Official safety notes indicate that older adults are more likely to need a dosage adjustment because the drug is cleared by the kidneys, which may function less efficiently with age. Additionally, the risk of severe respiratory depression (breathing issues) is documented as heightened in older adults when Neuroplex is used in combination with central nervous system depressants, such as opioids.

Q: Is Neuroplex approved by the FDA?

Yes, the active ingredient in Neuroplex is listed in the official prescribing information published by the U.S. Food and Drug Administration. This approval confirms that the medication is sanctioned by the FDA and other global regulatory bodies for use in its labeled indications.

Q: Can Neuroplex affect my ability to drive or operate machinery?

Regulatory warnings caution that Neuroplex commonly causes dizziness and somnolence (drowsiness). Regulatory warnings state that these effects may impair the ability to perform skilled tasks such as driving or operating machinery.

Q: Does Neuroplex cause weight gain or weight loss?

Clinical trial data included in the official safety profile indicate that weight gain is a common adverse reaction for patients taking Neuroplex. Conversely, weight loss is not identified as a common side effect in regulatory documents.

Q: What are the signs of a severe allergic reaction to Neuroplex?

Regulatory labeling highlights the risk of serious allergic and systemic reactions, including anaphylaxis and DRESS (Drug Reaction with Eosinophilia and Systemic Symptoms). Signs of these reactions may involve widespread rash, hives, difficulty breathing, fever, or swelling of the face, lips, throat, or tongue.

Q: How is Neuroplex eliminated from the body?

According to official clinical pharmacology information, Neuroplex is eliminated almost entirely by the kidneys without being metabolized (broken down) in the liver. This direct clearance mechanism is the reason regulatory guidance addresses the need for dose adjustments for patients with known kidney impairment.

Q: Does Neuroplex cause problems with my liver or kidneys?

Official sources state the drug is not metabolized by the liver, which suggests a low risk for metabolic liver issues. However, since the kidneys are responsible for eliminating the drug, regulatory documents address the need for a dosage adjustment for patients who have existing kidney impairment to prevent the drug from building up.

Q: Is Neuroplex meant to be taken every day?

The official administration instructions define a titration schedule that progresses to a daily therapeutic maintenance range. The dosing schedule indicates it is typically structured for ongoing use in approved conditions.

Q: Do effectiveness studies show Neuroplex works for everyone who takes it?

Studies reviewed by regulatory bodies indicate that a certain proportion of participants achieve clinically relevant improvement compared to those taking a placebo. As with most medications, responses are variable, and evidence suggests that not all patients may experience the same level of beneficial effect.

Q: How long after taking Neuroplex can I take certain other medications?

Official interaction statements mandate a time separation only for antacids that contain aluminum or magnesium, which must be taken at least two hours apart from Neuroplex. For the majority of other medications, regulatory information does not require a specific separation time.

Q: What is the average time before I know if Neuroplex is right for me?

Clinical studies often used four to six weeks of treatment as the primary assessment point to measure changes in reported pain scores. This time frame is generally indicative of the duration clinicians may use to evaluate initial therapeutic effectiveness.

Q: What are the general expectations for someone starting Neuroplex?

The treatment schedule typically involves starting with a low dose that is gradually adjusted over time (titration). It is common to experience side effects such as dizziness and somnolence (drowsiness) during the initial phase. Studies suggest that the assessment of full therapeutic effect may take several weeks.

Q: How quickly can I expect Neuroplex to start working?

Pharmacokinetic data show that the concentration of the active ingredient in the bloodstream usually peaks about 2 to 3 hours after taking a dose. However, the time it takes to notice a full clinical benefit, such as a reduction in pain or improved seizure control, can vary greatly from person to person.

Q: Is Neuroplex a type of narcotic or controlled substance?

Federally, the active ingredient in Neuroplex is not listed as a controlled substance. However, due to reports of misuse potential, a number of U.S. states have classified it as a Schedule V controlled substance. Schedule V is the federal classification designated for substances with the lowest relative potential for dependence or abuse.

Q: Why does the official document mention certain medical conditions for those who cannot use Neuroplex?

Conditions like impaired kidney function are mentioned in official documents because the drug is cleared from the body primarily by the kidneys. If kidney function is compromised, the drug cannot be eliminated effectively and can build up, which raises the risk of side effects. This accumulation is why dosage adjustment is required in these cases.

Q: How long does the effect of a Neuroplex dose typically last?

Official clinical pharmacology information indicates that the elimination half-life is typically 5 to 7 hours in patients with normal kidney function. The half-life refers to the time it takes for the amount of drug in the body to be reduced by half.

Q: Can Neuroplex affect my blood pressure?

Changes in blood pressure are not cited as common adverse reactions in the official safety profile. However, regulatory documents note that low blood pressure has been reported in cases involving acute overdose of the medication.

Q: Does taking Neuroplex long-term lead to dependence?

Official post-marketing experience reports have included cases of abuse and dependence, particularly in patients with a history of substance abuse. Official warnings note that patients with a history of substance abuse may be documented as being at a higher risk.

Q: Are there any known issues with taking Neuroplex with supplements or vitamins?

Standard multivitamin products are not documented as having a major interaction with Neuroplex. The primary concern noted in guidance is a risk of additive sedation. Therefore, official information notes the potential for enhanced sedative effects, particularly with supplements known to cause drowsiness.

Q: What is the risk of Neuroplex interacting with herbal remedies?

The main regulatory concern regarding herbal remedies is a pharmacodynamic interaction. Herbal remedies known to cause dizziness, drowsiness, or sedation may increase these same side effects when taken with Neuroplex.

Q: What happens if I take too much Neuroplex by accident?

Taking too much Neuroplex by accident can result in symptoms such as profound drowsiness, impaired coordination, dizziness, and low blood pressure. In serious cases, overdose can lead to lethargy and coma. Official guidance specifies that any suspected overdose must be immediately reported to a healthcare provider.

Q: Can Neuroplex cause a metallic taste or dry mouth?

Official reports from clinical studies list dry mouth as a possible adverse reaction. However, a metallic or altered taste is not commonly cited in the regulatory documents among the frequent side effects of Neuroplex.

Q: Does Neuroplex interact with birth control pills?

Studies reviewed by regulatory bodies indicate that Neuroplex does not significantly affect the way certain common oral contraceptives are processed by the body. Specifically, it has not been found to change the concentration of contraceptives containing norethindrone acetate and ethinyl estradiol, which suggests a low risk of interference with their effectiveness.

How should Neuroplex be stored and disposed of?

Official Storage and Disposal Instructions

Storage requirements for Neuroplex (Gabapentin) vary by formulation, as specified in regulatory documents. The medicine must always be kept out of the sight and reach of children.

Dosage Form Mandatory Storage Condition Environmental Protection
Capsules/Tablets Store at 20 C to 25 C; do not refrigerate. Protect from light and moisture; keep in original, tightly closed container.
Oral Solution Store in the refrigerator (2 C to 8 C); do not freeze. Keep in a tightly closed container.

All forms of Neuroplex must not be used past the expiry date. For disposal, the preferred method is a drug take-back program. The medication must not be flushed down the toilet or sink unless directed by specific labeling.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Neuroplex found in:

A-Z Index: